Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)

Vaccine

Volumn 19, Issue 20-22, 2001, Pages 2965-2974

  Conacher, Margaret ^a   Alexander, James ^b   Brewer, James M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Bile salts; Non ionic surfactant vesicles; Oral immunisation

Indexed keywords

BILE SALT; BILOSOME; BOVINE SERUM ALBUMIN; DEOXYCHOLIC ACID; INFLUENZA VACCINE; INTERLEUKIN 2; LIPOSOME; MEASLES VACCINE; NONIONIC SURFACTANT; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FORMULATION; FEMALE; INFLUENZA; INFLUENZA VACCINATION; LIPID VESICLE; MEASLES; MEASLES VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; ANTIGENS; BILE ACIDS AND SALTS; CHEMISTRY, PHARMACEUTICAL; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; INTERLEUKIN-10; INTERLEUKIN-2; LIPIDS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; SERUM ALBUMIN, BOVINE;

EID: 0035815518     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00537-5     Document Type: Article

References (58)

1. Oral immunization: Past and present
2. Oral vaccine models: Multiple delivery systems employing tetanus toxoid
3. Optimal delivery of vaccines
4. Structural requirements for intestinal absorption of peptide drugs
5. Oral vaccination: Identification of classes of proteins that provoke an immune response
6. Oral tolerance and regulation of immunity to dietary antigens
7. Oral tolerance
8. Oral immunization with influenza virus in biodegradable microspheres
9. Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (D,L-lactide-co-glycolide) microspheres
10. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles
11. Mucosal immunoadjuvant activity of liposomes: Role of alveolar macrophages
12. Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system
13. Comparative antibody responses and protection in mice immunised by oral or parenteral routes with influenza virus subunit antigens in aqueous form or incorporated into ISCOMs
14. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS
15. Oral immunization with simian immunodeficiency virus p55 (gag) and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates
16. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine
17. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli
18. MDP-Lys (L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice
19. Non-ionic surfactant vesicles as vaccine delivery systems
20. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen
21. Studies on the adjuvant activity of non-ionic surfactant vesicles: Adjuvant-driven IgG2a production independent of MHC control
22. An adjuvant formulation that preferentially induces T helper cell type 1 cytokine and CD8+ cytotoxic responses is associated with up-regulation of IL-12 and suppression of IL-10 production
23. Immune responses in mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery systems
24. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin
25. Studies on the mechanism of bile salt-induced liposomal membrane damage
26. Antibody responses to nonimmunogenic synthetic peptides induces by co-immunization with immunogenic peptides
27. Liposomes with a large trapping capacity prepared by freezing and thawing of sonicated phospholipid mixtures
28. Accurate determination of adjuvant-associated protein or peptide by ninhydrin assay
29. Enhancement of the intestinal absorption of peptides and non-peptides
30. Changing needs in drug delivery
31. The stability of liposomes in vitro to pH, bile salts and pancreatic lipase
32. Gastrointestinal uptake of liposomes. I. In vitro and in situ studies
33. Duodenal bile acid concentrations in fat malabsorption syndromes
34. Membranes and bile formation. Composition of several mammalian biles and their membrane-damaging properties
35. Presentation of peptides and proteins by intestinal epithelial cells
36. Activation patterns of murine T cells after oral administration of an enterocoated soluble antigen
37. ISCOMs - A novel strategy for mucosal immunization?
38. Biodegradable microparticles for oral immunization
39. Induction of immunological paralysis in two zones of dosage
40. The role of IL-10 in crossregulation of Th1 and Th2 responses
41. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells
42. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
43. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin
44. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A)
45. Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: Role in protection against influenza A in mice
46. Immune responses mediated by liposome-associated protein antigens. I. Potentiation of the plaque forming response
47. Mucosal immunoadjuvant activity of liposomes: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes
48. Liposomes as a mucosal adjuvant system: An intranasal liposomal influenza subunit vaccine and the role of IgA in nasal anti-influenza immunity
49. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens
50. Biodegradable microspheres for the delivery of oral vaccines
51. Enteric immunization of mice against influenza with recombinant vaccinia
52. Secretory antibody following oral influenza immunization
53. Improvement of inactivated influenza virus vaccines
54. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection
55. IgG2a restriction of murine antibodies elicited by viral infections
56. The IgA and subclass IgG responses and protection in mice immunised with influenza antigens administered as ISCOMs, with FCA, ALH or as infectious virus
57. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties
58. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles